ImmunoPrecise Antibodies Ltd. (HYFT) - Net Assets
Based on the latest financial reports, ImmunoPrecise Antibodies Ltd. (HYFT) has net assets worth $17.70 Million USD as of October 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($26.10 Million) and total liabilities ($8.40 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of ImmunoPrecise Antibodies Ltd. to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $17.70 Million |
| % of Total Assets | 67.83% |
| Annual Growth Rate | 6.92% |
| 5-Year Change | -58.5% |
| 10-Year Change | 2501.22% |
| Growth Volatility | 119.34 |
ImmunoPrecise Antibodies Ltd. - Net Assets Trend (1997–2025)
This chart illustrates how ImmunoPrecise Antibodies Ltd.'s net assets have evolved over time, based on quarterly financial data. Also explore total assets of ImmunoPrecise Antibodies Ltd. for the complete picture of this company's asset base.
Annual Net Assets for ImmunoPrecise Antibodies Ltd. (1997–2025)
The table below shows the annual net assets of ImmunoPrecise Antibodies Ltd. from 1997 to 2025. For live valuation and market cap data, see market value of ImmunoPrecise Antibodies Ltd..
| Year | Net Assets | Change |
|---|---|---|
| 2025-04-30 | $23.63 Million | -30.35% |
| 2024-04-30 | $33.92 Million | -41.32% |
| 2023-04-30 | $57.80 Million | -23.06% |
| 2022-04-30 | $75.13 Million | +31.99% |
| 2021-04-30 | $56.92 Million | +277.33% |
| 2020-04-30 | $15.09 Million | -16.51% |
| 2019-04-30 | $18.07 Million | +42.24% |
| 2018-04-30 | $12.70 Million | +310.83% |
| 2017-04-30 | $3.09 Million | +240.44% |
| 2016-04-30 | $908.26K | +535.57% |
| 2015-04-30 | $-208.52K | -29.35% |
| 2014-04-30 | $-161.21K | +25.25% |
| 2013-04-30 | $-215.66K | -79.88% |
| 2012-04-30 | $-119.89K | -195.29% |
| 2011-04-30 | $125.81K | -97.66% |
| 2010-04-30 | $5.37 Million | -20.91% |
| 2009-04-30 | $6.78 Million | +32.42% |
| 2008-04-30 | $5.12 Million | -5.18% |
| 2007-04-30 | $5.40 Million | +38.23% |
| 2006-04-30 | $3.91 Million | -7.56% |
| 2005-04-30 | $4.23 Million | +203.16% |
| 2004-04-30 | $1.39 Million | +52.89% |
| 2003-04-30 | $912.21K | +31.91% |
| 2002-04-30 | $691.56K | +163.72% |
| 2001-04-30 | $262.24K | -33.87% |
| 2000-04-30 | $396.53K | -75.52% |
| 1999-04-30 | $1.62 Million | -43.42% |
| 1998-04-30 | $2.86 Million | -21.06% |
| 1997-04-30 | $3.63 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ImmunoPrecise Antibodies Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12262718900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $136.37 Million | 577.21% |
| Other Comprehensive Income | $3.22 Million | 13.61% |
| Other Components | $12.83 Million | 54.32% |
| Total Equity | $23.63 Million | 100.00% |
ImmunoPrecise Antibodies Ltd. Competitors by Market Cap
The table below lists competitors of ImmunoPrecise Antibodies Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Schnapp
TA:SHNP
|
$56.50 Million |
|
Hannan Metals Ltd
V:HAN
|
$56.53 Million |
|
General Commercial & Industrial S.A
AT:GEBKA
|
$56.54 Million |
|
DIVA Laboratories Ltd
TWO:4153
|
$56.56 Million |
|
Pansari Developers Limited
NSE:PANSARI
|
$56.47 Million |
|
San Neng Group Holdings Co Ltd
TW:6671
|
$56.46 Million |
|
Duroc AB (publ)
ST:DURC-B
|
$56.46 Million |
|
Yellow Balloon Tour Co. Ltd
KQ:104620
|
$56.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ImmunoPrecise Antibodies Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 33,921,000 to 23,626,000, a change of -10,295,000 (-30.3%).
- Net loss of 29,974,707 reduced equity.
- New share issuances of 12,228,000 increased equity.
- Other comprehensive income increased equity by 1,191,000.
- Other factors increased equity by 6,260,707.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-29.97 Million | -126.87% |
| Share Issuances | $12.23 Million | +51.76% |
| Other Comprehensive Income | $1.19 Million | +5.04% |
| Other Changes | $6.26 Million | +26.5% |
| Total Change | $- | -30.35% |
Book Value vs Market Value Analysis
This analysis compares ImmunoPrecise Antibodies Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.71x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.05x to 1.71x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-04-30 | $23.89 | $1.21 | x |
| 1998-04-30 | $18.86 | $1.21 | x |
| 1999-04-30 | $10.63 | $1.21 | x |
| 2000-04-30 | $2.60 | $1.21 | x |
| 2001-04-30 | $1.71 | $1.21 | x |
| 2002-04-30 | $3.87 | $1.21 | x |
| 2003-04-30 | $4.14 | $1.21 | x |
| 2004-04-30 | $5.36 | $1.21 | x |
| 2005-04-30 | $13.56 | $1.21 | x |
| 2006-04-30 | $10.56 | $1.21 | x |
| 2007-04-30 | $14.26 | $1.21 | x |
| 2008-04-30 | $12.22 | $1.21 | x |
| 2009-04-30 | $14.27 | $1.21 | x |
| 2010-04-30 | $9.75 | $1.21 | x |
| 2011-04-30 | $0.23 | $1.21 | x |
| 2012-04-30 | $-0.22 | $1.21 | x |
| 2013-04-30 | $-0.41 | $1.21 | x |
| 2014-04-30 | $-0.24 | $1.21 | x |
| 2015-04-30 | $-0.38 | $1.21 | x |
| 2016-04-30 | $0.45 | $1.21 | x |
| 2017-04-30 | $0.78 | $1.21 | x |
| 2018-04-30 | $1.39 | $1.21 | x |
| 2019-04-30 | $1.44 | $1.21 | x |
| 2020-04-30 | $1.11 | $1.21 | x |
| 2021-04-30 | $3.46 | $1.21 | x |
| 2022-04-30 | $3.82 | $1.21 | x |
| 2023-04-30 | $2.32 | $1.21 | x |
| 2024-04-30 | $1.32 | $1.21 | x |
| 2025-04-30 | $0.71 | $1.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ImmunoPrecise Antibodies Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -126.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -123.30%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 1.88x
- Recent ROE (-126.87%) is above the historical average (-183.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | -19.86% | -11041.18% | 0.00x | 1.07x | $-1.08 Million |
| 1998 | -26.68% | -1317193.10% | 0.00x | 1.02x | $-1.05 Million |
| 1999 | -77.19% | -2371.67% | 0.03x | 1.02x | $-1.41 Million |
| 2000 | -313.98% | -16414.49% | 0.02x | 1.03x | $-1.28 Million |
| 2001 | -51.21% | -40696.06% | 0.00x | 4.42x | $-160.52K |
| 2002 | -34.04% | -60986.27% | 0.00x | 1.27x | $-304.56K |
| 2003 | -31.13% | 0.00% | 0.00x | 1.02x | $-375.22K |
| 2004 | -40.51% | 0.00% | 0.00x | 1.04x | $-704.47K |
| 2005 | -4.42% | 0.00% | 0.00x | 1.01x | $-609.81K |
| 2006 | -10.63% | 0.00% | 0.00x | 1.04x | $-806.21K |
| 2007 | -7.69% | 0.00% | 0.00x | 1.03x | $-955.63K |
| 2008 | -13.53% | 0.00% | 0.00x | 1.01x | $-1.21 Million |
| 2009 | -7.06% | 0.00% | 0.00x | 1.02x | $-1.16 Million |
| 2010 | -17.00% | 0.00% | 0.00x | 1.02x | $-1.45 Million |
| 2011 | -4081.76% | 0.00% | 0.00x | 1.68x | $-5.15 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-271.14K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-74.04K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $84.11K |
| 2015 | 0.00% | -3.54% | 38.24x | 0.00x | $-41.61K |
| 2016 | -3.80% | -1.82% | 1.37x | 1.52x | $-125.32K |
| 2017 | -180.14% | -204.67% | 0.69x | 1.27x | $-5.88 Million |
| 2018 | -40.91% | -95.03% | 0.22x | 1.93x | $-6.47 Million |
| 2019 | -43.02% | -69.72% | 0.39x | 1.57x | $-9.58 Million |
| 2020 | -34.34% | -35.19% | 0.54x | 1.81x | $-6.69 Million |
| 2021 | -12.89% | -40.98% | 0.27x | 1.18x | $-13.03 Million |
| 2022 | -22.70% | -86.29% | 0.21x | 1.24x | $-24.62 Million |
| 2023 | -47.08% | -128.53% | 0.27x | 1.35x | $-32.99 Million |
| 2024 | -77.91% | -106.51% | 0.41x | 1.77x | $-29.82 Million |
| 2025 | -126.87% | -123.30% | 0.55x | 1.88x | $-32.34 Million |
Industry Comparison
This section compares ImmunoPrecise Antibodies Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ImmunoPrecise Antibodies Ltd. (HYFT) | $17.70 Million | -19.86% | 0.47x | $56.50 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About ImmunoPrecise Antibodies Ltd.
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock ther… Read more